Preoperative Prediction of Axillary Lymph Node Metastasis in Breast Cancer Using a Three-tier MRI Radiomics Model with Nested Cross-validation
Academic Radiology · 2026-06 · 33 (6) · 2521-2532
DOI: 10.1016/j.acra.2026.02.024 ↗Kurz gefasst
Validierungsstudie in der Zeitschrift Academic Radiology, 2026-06. Verfasst von Hong Li und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiology, The Second Affiliated Hospital, Guangzhou Medical University, Guangzhou, Guangdong, China (H.L., W.H., J.L., S.H., H.C.). El…. Hauptthemen laut MEDLINE: Radiomics, Lymphatic Metastasis, Breast Neoplasms, Magnetic Resonance Imaging. Die Arbeit nennt 49 Literaturangaben.
Abstract (Originalsprache)
RATIONALE AND OBJECTIVES To develop and validate a three-tier model incorporating clinical, qualitative magnetic resonance imaging (MRI), and radiomics features for preoperative prediction of axillary lymph node (ALN) metastasis in breast cancer, using nested cross-validation to ensure unbiased performance estimates. MATERIALS AND METHODS This retrospective study included 494 patients with pathologically confirmed breast cancer who underwent preoperative MRI (dynamic contrast-enhanced [DCE] and T2FS-STIR sequences) between July 2018 and August 2024. Three progressive models were developed as follows: Model 1 (clinical variables: age, tumor size, estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2), Model 2 (Model 1 + qualitative MRI features: peritumoral edema, time-intensity curve pattern, multifocality, field strength), and Model 3 (Model 2 + radiomics scores from DCE and T2FS sequences). Radiomics features were extracted using PyRadiomics and selected through variance-correlation-univariate-LASSO filtering. True nested five-fold cross-validation repeated three times ensured that feature selection and model training were performed independently within each training fold. Model performance was compared using Delong test with Bonferroni correction. SHAP analysis provided model interpretability. RESULTS Model 3 achieved significantly higher AUC (0.769, 95% CI: 0.724-0.808) compared to Model 1 (0.676, 95% CI: 0.626-0.722; ΔAUC = +0.093, p
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Radiology, The Second Affiliated Hospital, Guangzhou Medical University, Guangzhou, Guangdong, China (H.L., W.H., J.L., S.H., H.C.). Electronic address: nicolelee123@163.com.
- Department of Radiology, The Second Affiliated Hospital, Guangzhou Medical University, Guangzhou, Guangdong, China (H.L., W.H., J.L., S.H., H.C.).
- College of Biomedical Engineering and Instrument Science, Key Laboratory for Biomedical Engineering of Ministry of Education, Zhejiang University, Hangzhou, Zhejiang province 310027, China (X.X.).
- GE Healthcare, Beijing, China (B.S.).
- Department of Radiology, The Second Affiliated Hospital, Guangzhou Medical University, Guangzhou, Guangdong, China (H.L., W.H., J.L., S.H., H.C.). Electronic address: chenhuai1977@163.com.
Zitieren
APA
Li, H., Huang, W., Liang, J., Huang, S., Xu, X., Shao, B., & Chen, H. (2026). Preoperative Prediction of Axillary Lymph Node Metastasis in Breast Cancer Using a Three-tier MRI Radiomics Model with Nested Cross-validation. Academic Radiology, 33(6), 2521-2532. https://doi.org/10.1016/j.acra.2026.02.024
Vancouver
Li H, Huang W, Liang J, Huang S, Xu X, Shao B, et al. Preoperative Prediction of Axillary Lymph Node Metastasis in Breast Cancer Using a Three-tier MRI Radiomics Model with Nested Cross-validation. Academic Radiology. 2026;33(6):2521-2532. doi:10.1016/j.acra.2026.02.024
BibTeX
@article{Li2026,
author = {Li, Hong and Huang, Weiqing and Liang, Jiefeng and Huang, Suidan and Xu, Xiaoyin and Shao, Beibei and Chen, Huai},
title = {Preoperative Prediction of Axillary Lymph Node Metastasis in Breast Cancer Using a Three-tier MRI Radiomics Model with Nested Cross-validation},
journal = {Academic Radiology},
year = {2026},
volume = {33},
number = {6},
pages = {2521--2532},
doi = {10.1016/j.acra.2026.02.024}
}
EUVIMED